解毒化瘀颗粒治疗慢加急性肝衰竭的临床疗效研究

发布时间：2018-06-17 04:03

本文选题：解毒化瘀颗粒 + 慢加急性肝衰竭　；参考：《广西中医药大学》2016年硕士论文

【摘要】：目的:通过随机对照临床研究,观察解毒化瘀颗粒治疗慢加急性肝衰竭的临床疗效,为解毒化瘀颗粒可降低慢加急性肝衰竭患者的死亡率提供循证医学证据。方法:采用随机、对照临床研究,将符合纳入标准的46例慢加急性肝衰竭患者随机分为治疗组与对照组,治疗组在西医综合治疗基础上加用解毒化瘀颗粒,对照组予西医综合治疗。观察的终点为8周。通过观察慢加急性肝衰竭患者死亡率、肝功能、凝血功能及中医证候评分等,评估解毒化瘀颗粒对慢加急性肝衰竭的临床疗效。结果:研究结果显示,解毒化瘀颗粒联合西医综合治疗的中西医结合方案能显著降低患者死亡率,并优于单纯西医综合治疗组(P0.05)。治疗组和对照组总有效率分别为69.57%和39.13%,差异有统计学意义(P0.05)。治疗后第4、第8周,各时间点两组患者TBiL对比差异均有统计学意义(P0.05),治疗组优于对照组。治疗后第4周两组患者PTA对比差异有统计学意义(P0.05),治疗组对于凝血功能的改善优于对照组,治疗后第8周,两组患者PTA对比差异无统计学意义(P0.05)。治疗8周后,两组患者中医证候评分均显著下降,治疗组与对照组各时间点相比差异均有统计学意义(P0.05),治疗组改善中医证候评分优于对照组。结论:应用解毒化瘀颗粒联合西医综合治疗方案,可显著改善慢加急性肝衰竭患者短期预后(8周),并能降低患者死亡率,提高肝功能复常率,促进凝血机制的恢复,总体临床疗效优于单纯西医综合治疗。
[Abstract]:Objective: to observe the clinical efficacy of jiedu Huayu granule in the treatment of chronic and acute liver failure by randomized controlled clinical study, and to provide evidence-based medical evidence for reducing the mortality rate of patients with chronic and acute liver failure. Methods: 46 patients with chronic and acute hepatic failure were randomly divided into treatment group and control group. The treatment group was treated with jiedu Huayu granule on the basis of comprehensive western medicine. The control group was treated with comprehensive western medicine. The end point of observation was 8 weeks. By observing the mortality rate, liver function, coagulation function and TCM syndrome score of patients with chronic and acute liver failure, the clinical efficacy of jiedu Huayu granule in treating chronic and acute liver failure was evaluated. Results: the results showed that the combined treatment of jiedu Huayu granule and western medicine could significantly reduce the mortality rate of patients, and was better than that of the simple integrated treatment group of western medicine (P0.05). The total effective rates of the treatment group and the control group were 69.57% and 39.13%, respectively. The difference was statistically significant (P 0.05). There were significant differences in TBiL between the two groups at the 4th and 8th week after treatment. The treatment group was superior to the control group. There was significant difference in PTA between the two groups at the 4th week after treatment. The improvement of coagulation function in the treatment group was better than that in the control group. At the 8th week after treatment, there was no significant difference in PTA contrast between the two groups (P 0.05). After 8 weeks of treatment, the TCM syndrome scores of the two groups were significantly decreased, the difference between the treatment group and the control group at each time point was statistically significant (P 0.05), and the improvement of TCM syndrome score in the treatment group was better than that in the control group. Conclusion: the combined treatment of jiedu Huayu granule and western medicine can significantly improve the short-term prognosis of patients with chronic and acute liver failure for 8 weeks, reduce the mortality of patients, increase the recovery rate of liver function, and promote the recovery of coagulation mechanism. The overall clinical efficacy is superior to that of western medicine alone.
【学位授予单位】：广西中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R259

【相似文献】